NOVS-100

About Celloram

Celloram is a private, preclinical-stage biotech founded in 2018 with a focus on small molecules and cell therapies for oncology, autoimmune, and metabolic diseases. The company has raised $9M in total funding from investors including MedPacto and Theragen Etex and is led by a seasoned team with deep expertise in cancer research and drug development. Its strategy centers on a dual-platform approach: developing novel small molecule inhibitors and dendritic cell-based immunotherapies designed to stimulate self-healing and enhance therapeutic efficacy. Celloram operates from its headquarters in Cleveland's University Circle, leveraging its academic connections for research and development.

Therapeutic Areas

Other Not Specified (Oncology/Immune/Metabolic Focus) Drugs